Skip to content
Stop using now Drug recall · FDA · Published October 1, 2025

Aspiro Pharma Recalls Ketorolac Injections Due to Glass Particles

Aspiro Pharma recalls specific lots of Ketorolac Tromethamine Injection due to glass particulate matter. Check lot numbers and expiration dates for affected vials.

🇺🇸 FDA recall #D-0036-2026DrugAspiro Pharma ›
Take action

Contact the company

Call(866) 495-1995
Recalling firmAspiro Pharma LimitedSurvey No. 321, Biotech Park, Phase Iii, Karkapatla Village, Markook (Mandal) · Siddipet (District), India
✎ GovInfoNow plain-language explainer

What happened, in plain English

Aspiro Pharma Limited has recalled Ketorolac Tromethamine Injection, USP, 60 mg/2 mL single-dose vials because particulate matter identified as glass was found in the product. The recall affects specific lots distributed nationwide within the United States. No remedy or contact information for consumers is currently provided in the record. Read more at govinfonow.com/recall/31763-aspiro-pharma-recalls-ketorolac-injections-due-to-glass-particles.

Source Summary by GovInfoNow · govinfonow.com/recall/31763-aspiro-pharma-recalls-ketorolac-injections-due-to-glass-particles · Updated October 9, 2026 · FDA enforcement record: FDA #D-0036-2026

Cite this page

“Aspiro Pharma Recalls Ketorolac Injections Due to Glass Particles.” GovInfoNow, updated October 9, 2026. https://govinfonow.com/recall/31763-aspiro-pharma-recalls-ketorolac-injections-due-to-glass-particles. Based on FDA recall #D-0036-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0036-2026%22&limit=1).

Why it’s dangerous

The presence of particulate matter identified as glass in the injection poses a serious safety risk. If injected, these particles can cause embolisms, tissue damage, or other severe complications at the injection site or elsewhere in the body.

Who’s affected

Patients prescribed Ketorolac Tromethamine Injection for intramuscular use who possess vials from the affected lots are at risk of exposure to glass particles. Healthcare providers administering this medication must also verify the lot numbers before use.

How to tell if you have this one

Check your vials for the following details: Product name 'Ketorolac Tromethamine Injection, USP, 60 mg/2 mL', NDC 31722-307-25 (Carton) or 31722-307-02 (Vial label). Affected lot numbers are AS1240347A (Exp 09/2026), AS1240144A (Exp 05/2026), AS1240145A, AS1240146A (Exp 06/2026), and AS1250295A (Exp 05/2027).

  • Brand
    Aspiro Pharma
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Verify Lot Numbers

    Check the vial label against the recalled lot numbers: AS1240347A, AS1240144A, AS1240145A, AS1240146A, and AS1250295A.

  2. Stop Use Immediately

    Do not use any vials that match the recalled lot numbers or contain visible particulate matter.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 28 days after the firm started it.

1. Firm started the recall: Oct 1, 202512. FDA classified it Class II: Oct 21, 202523. Published in FDA’s Enforcement Report: Oct 29, 202532025
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Take action

Contact Aspiro Pharma

We’ve drafted a message you can send Aspiro Pharma to request your refund or repair — edit it as you like.

Subject: Recall D-0036-2026 — Aspiro Pharma Recalls Ketorolac Injections Due to Glass Particles

Hello,

I own a Aspiro Pharma Recalls Ketorolac Injections Due to Glass Particles that is covered by recall D-0036-2026 from Aspiro Pharma.

I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this?

Thank you.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0036-2026 (October 1, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0036-2026 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 9, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA